Trial Profile
A Randomized, Double-blind, Multi-center Study to Assess Safety and Tolerability of Different Oral Doses of BAY94-8862 in Subjects With Stable Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease Versus Placebo (Part A) or Versus Placebo and Spironolactone (Part B)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Finerenone (Primary) ; Spironolactone
- Indications Chronic heart failure
- Focus Pharmacodynamics
- Acronyms ARTS
- Sponsors Bayer; Bayer HealthCare
- 06 Dec 2020 Results published in the Nephrology Dialysis Transplantation
- 01 Sep 2012 Planned number of patients changed from 420 to 425.
- 29 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.